Renaissance Technologies (RenTech)'s EDIT Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 2.47 M shares of Editas Medicine, Inc. (EDIT) worth $8 M, representing 0.01% of the portfolio. First purchased in 2016-Q2, this long-term strategic position has been held for 31 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in EDIT, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 1.76 M shares. Largest reduction occurred in Q2 2026, reducing 1.5 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Editas Medicine (EDIT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Editas Medicine (EDIT) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -1.5 M | Reduce 37.84% | 2.47 M | $3.24 |
| Q1 2026 | +932,382 | Add 30.67% | 3.97 M | $2.47 |
| Q4 2025 | +1.76 M | Add 137.97% | 3.04 M | $2.05 |
| Q3 2025 | +389,000 | Add 43.79% | 1.28 M | $3.47 |
| Q2 2025 | -144,565 | Reduce 14.00% | 888,400 | $2.20 |
| Q1 2025 | -418,084 | Reduce 28.81% | 1.03 M | $1.16 |
| Q4 2024 | +1.45 M | New Buy | 1.45 M | $1.27 |
| Q3 2024 | -98,429 | Sold Out | 0 | $0.00 |
| Q2 2024 | -799,989 | Reduce 89.04% | 98,429 | $4.67 |
| Q1 2024 | +391,018 | Add 77.06% | 898,418 | $7.42 |
| Q4 2023 | +442,900 | Add 686.67% | 507,400 | $10.13 |
| Q3 2023 | -91,800 | Reduce 58.73% | 64,500 | $7.80 |
| Q2 2023 | +156,300 | New Buy | 156,300 | $0.01 |
| Q2 2022 | -903,400 | Sold Out | 0 | $0.00 |
| Q1 2022 | +675,300 | Add 296.05% | 903,400 | $19.02 |
| Q4 2021 | +228,100 | New Buy | 228,100 | $26.55 |
| Q3 2021 | -140,000 | Sold Out | 0 | $0.00 |
| Q2 2021 | -315,927 | Reduce 69.29% | 140,000 | $56.64 |
| Q1 2021 | +455,927 | New Buy | 455,927 | $42.00 |
| Q4 2020 | -106,100 | Sold Out | 0 | $0.00 |
| Q3 2020 | -94,000 | Reduce 46.98% | 106,100 | $28.06 |
| Q2 2020 | -100,800 | Reduce 33.50% | 200,100 | $29.58 |
| Q1 2020 | +218,800 | Add 266.50% | 300,900 | $19.83 |
| Q4 2019 | +82,100 | New Buy | 82,100 | $29.61 |
| Q2 2019 | -371,400 | Sold Out | 0 | $0.00 |
| Q1 2019 | +99,400 | Add 36.54% | 371,400 | $24.45 |
| Q4 2018 | -28,100 | Reduce 9.36% | 272,000 | $22.75 |
| Q3 2018 | +300,100 | New Buy | 300,100 | $31.82 |
| Q4 2016 | -128,400 | Sold Out | 0 | $0.00 |
| Q3 2016 | +106,096 | Add 475.68% | 128,400 | $13.48 |
| Q2 2016 | +22,304 | New Buy | 22,304 | $24.39 |
Renaissance Technologies (RenTech)'s Editas Medicine Investment FAQs
Renaissance Technologies (RenTech) first purchased Editas Medicine, Inc. (EDIT) in Q2 2016, acquiring 22,304 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Editas Medicine, Inc. (EDIT) for 31 quarters since Q2 2016.
Renaissance Technologies (RenTech)'s largest addition to Editas Medicine, Inc. (EDIT) was in Q4 2025, adding 3,039,778 shares worth $6.23 M.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 2,468,919 shares of Editas Medicine, Inc. (EDIT), valued at approximately $8 M.
As of the Q2 2026 filing, Editas Medicine, Inc. (EDIT) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Editas Medicine, Inc. (EDIT) was 3,972,160 shares, as reported at the end of Q1 2026.